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Background. Influenza virus infection is a major public health burden worldwide. Available vaccines include
the inactivated intramuscular trivalent vaccine and, more recently, an intranasal live attenuated influenza vaccine
(LAIV). The measure of successful vaccination with the inactivated vaccine is a systemic rise in immunoglobulin
G (IgG) level, but for the LAIV no such correlate has been established.
Methods. Seventy-nine subjects were given the LAIV FluMist. Blood was collected prior to vaccination and 3
days and 30 days after vaccination. Nasal wash was collected 3 days and 30 days after vaccination. Responses were
measured systemically and in mucosal secretions for cytokines, cell activation profiles, and antibody responses.
Results. Only 9% of subjects who received LAIV seroconverted, while 33% of patients developed at least a
2-fold increase in influenza virus–specific immunoglobulin A (IgA) antibodies in nasal wash. LAIV induced a
localized inflammation, as suggested by increased expression of interferon-response genes in mucosal RNA and
increased granulocyte colony-stimulating factor (G-CSF) and IP-10 in nasal wash. Interestingly, patients who
seroconverted had significantly lower serum levels of G-CSF before vaccination.
Conclusions. Protection by LAIV is likely provided through mucosal IgA and not by increases in systemic
IgG. LAIV induces local inflammation. Seroconversion is achieved in a small fraction of subjects with a lower
serum G-CSF level.
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Influenza is an acute viral respiratory infection that
results in high morbidity and significant mortality in
humans, producing significant health and economical
burdens worldwide [1]. Annual vaccination has been the
most effective strategy to reduce the impact of influenza
virus infection [2]. As a consequence, significant effort
has been made to produce effective vaccines that will
reduce the incidence and severity of natural infections.
In the United States, the use of intramuscular triva-
lent inactivated influenza vaccine (TIV) is
recommended to induce protective immunity through
the induction of serum antibodies. Recently, a live at-
tenuated influenza vaccine (LAIV) delivered by intra-
nasal spray was licensed [3–5]. LAIV induces an
immune response that more closely resembles natural
immunity than the response elicited by the intramus-
cular vaccine [6, 7]. This vaccine provides comparable
levels of protection against laboratory-documented in-
fluenza in adults (85% efficacy), compared with TIV
[8, 9], but the mechanism of action might be different.
Lower serum hemagglutination-inhibition (HAI) titers
are seen with LAIV, and they are accompanied by a
higher level of immunoglobulin A (IgA) antibodies in
nasal wash [8–11], suggesting that other immunologi-
cal contributors may be involved in the protection fol-
lowing vaccination with LAIV.
Although systems biology approaches have been
used to predict the immunogenicity of the vaccine YF-
17D against yellow fever [12] and, more recently, of
TIV and LAIV against influenza [13], the latter study
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did not examine the mucosal response to LAIV. The present
study extends what is known about the systemic response and
provides information about the local response to LAIV.
To identify factors associated with LAIV vaccination, we
performed a study during the 2010–2011 influenza season.
We developed a protocol to evaluate the immunological
changes in systemic and local (upper respiratory tract)
immune responses and collected blood samples and nasal se-
cretions from 79 healthy adult subjects who were vaccinated
with LAIV. Our study indicates that LAIV receipt induces a
local inflammatory response, triggering nasal release of inter-
feron (IFN) and granulocyte colony-stimulating factor
(G-CSF) 2–3 days after vaccination, followed by specific




The study was performed at Mount Sinai Medical Center in
New York City. All subjects provided informed consent on en-
rollment. The vaccination period was 5 October 2010 through
21 December 2010. This study was approved by the Mount
Sinai School of Medicine Institutional Review Board.
Eligibility criteria were based on the Centers for Disease
Control and Prevention’s and manufacturer’s guidance for the
administration of the intranasal LAIV [2, 14]. Healthy, nonfe-
brile individuals aged 18–49 years were eligible. Individuals
who reported recent influenza, previous receipt of influenza
vaccine during the 2010–2011 seasons, asthma, concurrent
pregnancy, allergy to the vaccine or its components, or
chronic medical conditions were excluded.
Vaccination
All subjects were inoculated with FluMist vaccine (2010–2011
formulation; MedImmune, Gaithersburg, MD). Each 2-mL
dose contained live attenuated influenza virus reassortants of
each of the 3 strains for the 2010–2011 season: A/California/
7/2009 (H1N1), A/Perth/16/2009 (H3N2), and B/Brisbane/60/
2008.
Study Protocol
At the initial study visit, subjects were administered a ques-
tionnaire to obtain baseline demographic information, influ-
enza vaccination history, and risk factors for influenza
infection. Phlebotomy was performed during the initial visit
prior to FluMist administration (day 0). Subjects returned for
a first follow-up visit 48-72 hours after administration (day 3).
At this first follow-up visit, a questionnaire assessed self-
reported postvaccination influenza symptoms (ie, fever, rhi-
norrhea, nasal congestion, sore throat, and cough). Blood
pressure, temperature, and heart rate were recorded, and a 10-
mL nasal wash and phlebotomy was performed. Subjects re-
turned for a second follow-up visit at least 30 days following
vaccination (day 30) for a 10-mL nasal wash and phlebotomy.
Nasal Wash
Nasal washes were performed using a method previously de-
scribed [15], by spraying sterile saline solution into the nostril
followed by collecting the expelling fluid in a specimen collec-
tion cup. Both nostrils were washed with 5 mL of saline solu-
tion, resulting in the nasal wash sample. Each nasal wash
sample was centrifuged at 500×g for 10 minutes to remove
cells and debris, and cell-free supernatant was stored in ali-
quots at −80°C. The cell pellet of the nasal wash sample was
processed for total RNA extraction using Trizol (Invitrogen).
Cell and Serum Isolation
Peripheral blood mononuclear cells (PBMCs) and serum
samples were collected from fresh blood, using ethylenedi-
aminetetraacetic acid–coated and serum Vacutainer tubes,
respectively (BD). Serum samples were stored and frozen at
−80° until analysis. PBMCs were isolated by Ficoll density
gradient separation (Histopaque, Sigma-Aldrich). CD14+ mono-
cytes were isolated by positive selection (Miltenyi Biotec). Mono-
cytes were lysed in Trizol (Invitrogen) and stored at −80°C.
Cytokine/Chemokine Analysis
All samples from serum and nasal wash were stored at −80°C
until the end of the study. Measurements of cytokines/chemo-
kines were performed as described before [16], using an 11-
plex cytokine panel (Millipore). All samples were run in dupli-
cate in accordance with the manufacturer’s protocol, using a
Luminex 200 (Luminex Corporation), and were analyzed
using Milliplex Analyst software.
Quantitative Real-Time Reverse Transcription Polymerase
Chain Reaction (qRT-PCR) and Gene Expression Analysis
Monocyte RNA extraction was performed using Trizol (Invi-
trogen). Concentrations of total RNA were determined using a
Nanodrop spectrophotometer. Reverse transcription was per-
formed using a First Strand Reverse Transcriptase kit (Roche).
qRT-PCR was performed using the Universal Probe Library
and the Master Mix 480 system for LightCycler (Roche). Gene
expression data were normalized to the average cycle threshold
(Ct) value of the housekeeping genes GAPDH and Rps13A,
and the difference in the normalized Ct value between days 3
and 0 was calculated. By use of the log2 fold-change on day 3
relative to day 0, unpaired t test analysis was done to compare
subjects who were negative for seroconversion with those who
were positive for seroconversion.
The cell pellet of the nasal wash sample was processed for
total RNA extraction, using Trizol (Invitrogen), and RNA was
amplified using the WT-Ovation RNA Amplification system
(NuGEN). Gene expression was analyzed by qRT-PCR, using
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a LightCycler 480 II (Roche). Gene expression was performed
as described above, and statistical analysis of the difference in
log2 values between days 3 and 30 was performed using a t
test involving a paired 2-sample analysis. In the analysis, only
patients with detectable messenger RNA (mRNA) levels on
days 3 and 30 after vaccination were considered. The gene ex-
pression data for MX1, STAT1, BST2, IRF7, and RIG1 are rep-
resentative of 25, 22, 10, 5, and 8 subjects, respectively.
HAI Assays
Titers from HAI assays were determined on the basis of stan-
dard protocol of the World Health Organization. Briefly,
serum samples were treated with receptor-destroying enzyme
(Sigma Aldrich) and then serially diluted with phosphate-
buffered saline (PBS) in 96-well round-bottom plates (Nunc).
Four HA units of influenza A virus subtype H1N1 was added
to each well. HAI titers were determined as the highest dilu-
tion that displayed hemagglutination activity.
Immunohistochemical (IHC) Staining
Madin-Darby canine kidney (MDCK) cells were seeded in 96-
well plates at 60% of confluence and cultured with Dulbecco’s
modified Eagle’s medium (Invitrogen) supplemented with
10% fetal bovine serum (FBS; Hyclone), L-glutamine, and pen-
icillin-streptomycin. On the next day, cells were washed and
infected at multiplicity of infection of 1.5 with the A/Califor-
nia/4/2009 (H1N1) influenza strain. One hour after infection,
cells were cultured with FBS-containing media and stored
overnight. Cells were harvested, washed with PBS, and fixed
with 1% paraformaldehyde in PBS for 5 minutes, after which
additional PBS washes were performed. Cells were blocked
with bovine serum albumin and then incubated at different
dilutions (from 1:10 to 1:20 000) of patient sera samples for 2
hours at room temperature. Cells were washed twice with PBS
and then incubated with anti-total IgG-HRP for 1 hour at
room temperature. Cells were washed twice and developed
using AEC substrate kit (BD Pharmingen). The IHC titer was
determined as the highest dilution that displayed
immunodetection.
IgA Quantification by Enzyme-Linked Immunosorbent Assay
(ELISA)
The HA-specific IgA antibody in nasal wash specimens was
determined by ELISA as previously described [8, 17], using as
antigen purified recombinant hemagglutinin (rHA) protein
from influenza virus A/California/04/2009 (H1N1), obtained
through the National Institutes of Health (NIH) Biodefense
and Emerging Infections Research Resources Repository.
Briefly, 96-well polystyrene plates were coated with rHA prior
to incubation with nasal wash samples overnight. The plates
were washed with PBS/0.1% Tween-20, followed by the addi-
tion of anti-human IgA-HRP (Bethyl Laboratories). ELISA
titers were calculated using the positive-negative (P/N) ratio,
in which the end point was the highest dilution with a P/N
ratio of ≥2. In the calculation, the optical density (OD) of an
antigen-coated well (positive) was divided by the OD of the
control well lacking the antigen (negative).
Heat Map and Statistical Analysis
To avoid the problems associated with computing the log
function and ratio, 1 was added to all ELISA concentrations.
The ELISA-determined concentration of 4 cytokines in each
patient’s nasal wash at the 2 visits was then transformed by
the function log2(x), and a Manhattan distance was computed
for each of 79 sample pairs, where each sample contains 8 cy-
tokine expressions (4 at the baseline visit and 4 at the postvac-
cination visit). A hierarchical clustering was performed on
these Manhattan distances with the agglomeration method
‘ward’ [18, 19], resulting in a dendrogram (clustering tree) that
places samples with smaller Manhattan distances in neighbor-
ing positions. While maintaining the constraints imposed by
the dendrogram, the 79 samples were further reordered ac-
cording to the average of the 8 transformed cytokine expres-
sion measurements. After the samples were reordered, a heat
map was generated for the 79 × 8 cytokine expression matrix.
Table 1. Demographic and Clinical Characteristics of 70 Adults
Who Received Intranasal Live Attenuated Influenza Vaccine
Characteristic Value
Age, y, mean ± SD 30.3 ± 7.2





White, non-Hispanic 40 (51)
Hispanic 18 (23)
Black, non-Hispanic 6 (8)
Asian 12 (15)
Other 3 (4)
Received 2009 H1N1 vaccine
Yes 24 (30)
No 50 (63)
Didn’t know/no answer 5 (6)
Received 2009 seasonal influenza vaccine
Yes 38 (48)
No 36 (46)
Didn’t know/no answer 5 (6)
Ever received FluMist 2 in 2009, 1 in 2005
Had ILI during 2009–2010 influenza season 7 (9)
Data are no. (%) of patients, unless otherwise indicated.
Abbreviations: H1N1, 2009 pandemic influenza A virus subtype H1N1; ILI,
influenza-like illness.
a Defined as the weight in kilograms divided by the square of the height in
meters.
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All heat map analyses were performed using the statistical pro-
gramming language R, version 2.13 (http://www.r-project.org)
[20, 21]. The box plot and the P values of paired Wilcoxon
tests were computed by the functions boxplot() and wilcox.
test(), respectively, in R, version 2.13 [20]
RESULTS
Subjects Characteristics
Seventy-nine subjects completed the study protocol. Baseline
demographic characteristics of the study cohort are described
in Table 1. In the study cohort, 24 patients (30%) reported
receipt during the previous year of 2009 pandemic influenza A
virus subtype H1N1, and 38 (48%) reported receipt of the
2009 trivalent seasonal influenza vaccine. Only 3 subjects (4%)
had previously received FluMist, and 7 subjects reported a
history of influenza-like illness during the 2009–2010 influen-
za season. Symptoms present 48–72 hours after vaccination
are described in Supplementary Table 1. Two subjects (3%)
reported fever following administration of the vaccine. Reports
of other symptoms varied, with 28% reporting rhinorrhea and
nasal congestion, 18% reporting sore throat, and 6% develop-
ing a mild cough. Overall, 40 subjects (51%) reported at least
1 symptom.
Systemic Antibody Response
All serum samples were analyzed for the production of anti-
bodies to both influenza A viruses included in the vaccine.
Figure 1. Systemic immunity after receipt of live attenuated influenza vaccine (LAIV). A, Hemagglutinin inhibition (HAI) titer in serum on day 30 after
LAIV vaccination relative to day 0 (before vaccination). Data are from 1 experiment with 79 subjects assayed in duplicate, using influenza A virus
subtype H1N1. Continued line represents subjects with a ≥4-fold increase above baseline (seroconversion). Dashed line represents subjects with a 2-
fold increase. B, Immunohistochemical analysis (IHC) to recognize serum antibodies against influenza A virus subtype H1N1. Data are the fold-increase
on day 30 relative to day 0. C, Cytokine concentrations on days 0 and 3 after vaccination were analyzed by multiplex enzyme-linked immunosorbent
assay (ELISA). The y-axis displays the transformed concentration of each cytokine, calculated as log2(1 + x), where x is the ELISA-determined value. G-
CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-monocyte colony-stimulating factor; IFN-α2, interferon α2; IFN-γ, interferon γ; IL-1b,
interleukin, 1b; IL-6, interleukin 6; IL-12p70, interleukin 12p70; TNF-α, tumor necrosis factor α. D, Box plots of serum levels of G-CSF on day 0 (left), G-
CSF on day 3 after vaccination (middle), and IFN-α2 on day 0 (right) between subjects who were positive (n = 9) or negative (n = 70) for seroconversion.
The top and bottom of each rectangle give the 75th and 25th percentiles, respectively, while the bold line in the middle of the rectangle gives the 50th
percentile. Outliers are indicated by open circles. *P < .05, by the paired Wilcoxon test.
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Most subjects had high prevaccine titers to the H3N2 compo-
nent (data not shown); as a result, we focused this study on
the response to the H1N1 component of the vaccine.
We determined HAI titers for influenza A virus subtype
H1N1 in serum samples at days 0 and 30 after vaccination.
Only 7 subjects (9%) were positive for seroconversion, with an
increase of at least 4-fold in the antibody response (Figure 1A),
a finding consistent with many published reports showing that
LAIV induces less serum antibody than TIV [8, 13, 22]. Serum
HAI titers are the most commonly measured correlates of pro-
tection, and a protective serum antibody response (defined as
an HAI titer of ≥1:40) [23] was detected in 34 subjects (43%)
prior to vaccination, indicating prior exposure to the antigen.
The majority of individuals who seroconverted in this study (6
subjects) showed a prevaccination HAI titer of 1:10 or less
(Table 2). None of the subjects who seroconverted reported
receiving the previous years’ influenza vaccine, and only 1
subject reported having influenza-like illness in the year previ-
ous to LAIV administration.
We further evaluated the serum antibody response by per-
forming IHC using MDCK cell monolayers infected with in-
fluenza A virus subtype H1N1 and incubated with dilutions of
serum collected at the time of vaccine administration or 30
days later. Nineteen subjects (24%) showed at least a 4-fold
increase in staining after vaccination (Table 2). By use of
this assay, 39% of subjects without preformed antibody
Table 2. Findings From Hemagglutination Inhibition (HAI) and Immunohistochemical (IHC) Analyses to Determine Serum Antibody
(Ab) Response to Intranasal Live Attenuated Influenza Vaccine
Group
HAI Findings IHC Findings
Log2 Ab Titer
Before Vaccination














2.44 ± 0.33 3.08 ± 1.29 6/33 (18) .008 4.56 ± 2.18 5.86 ± 2.34 13/33 (39) .023
Data are mean ± SD, unless otherwise indicated. HAI analysis was performed using A/California/4/2009 (H1N1) influenza virus. IHC analysis was performed
using Madin-Darby canine kidney cells infected with A/California/4/2009 (H1N1) influenza virus to detect immunoglobulin G Ab to the virus.
a Measured on day 30 after vaccine receipt.
b Defined as a ≥4-fold increase in titer between samples obtained before and after vaccination. Data are no. of seroconverted vaccine recipients/total no. of
vaccine recipients (%).
c Comparison of vaccine Ab levels before and after vaccination, calculated by a 2-tailed unpaired Student t test.
Figure 2. Analysis of gene expression induced by live attenuated influenza vaccine receipt in monocytes of peripheral blood, using quantitative
reverse transcription polymerase chain reaction analysis of CD14+ monocytes on day 0 and 3 after vaccination. Fold-changes in expression are shown as
the mean of the log2 value between days 3 and 0 for 7 subjects who were negative for seroconversion (−) and 5 subjects who were positive for
seroconversion (+). Error bars represent the standard error of the mean. *P < .05.
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seroconverted (Figure 1B), suggesting that a systemic response
to nasally administered LAIV can be seen with highly sensitive
assays in subjects with low preformed antibody titers.
Serum Cytokine Levels
During virus infection, a rise in levels of several cytokines
occurs in serum 48–72 hours after infection [24]. To determine
whether LAIV causes a systemic change in serum levels of cyto-
kines, samples collected at the time of vaccination and 3 days
later were analyzed by multiplex ELISA. No predictable patterns
could be detected in the measured cytokines (Figure 1C and
Supplementary Table 2). In contrast to virus infection, LAIV
does not appear to trigger a change in serum cytokine profiles.
Analysis of baseline serum cytokine expression was per-
formed to determine the influence of serum cytokines on the
systemic antibody response to LAIV. While subjects who sero-
converted had slightly lower levels of IFN-α2 in blood than
those who did not, the difference did not reach statistical sig-
nificance (P = .30). Interestingly, subjects who seroconverted
had significantly less G-CSF in prevaccine sera than subjects
who did not seroconvert (P = .047 on day 0 and P = .025 on
day 3; Figure 1D).
Monocyte Gene Expression Following Administration of LAIV
Monocytes are an important element of the response to virus
infection and have been shown to be in an activated state in
the blood and bone marrow of influenza virus–infected mice
[25]. To determine whether monocytes become activated fol-
lowing LAIV administration, cells were isolated from the
blood of subjects at the time of vaccination and 3 days later to
measure gene expression associated with antiviral immunity.
Subjects who seroconverted, as determined by both HAI
and IHC assays, were compared to randomly selected subjects
who did not seroconvert (all were vaccinated but had no de-
tectable systemic antibody response). Among the genes ana-
lyzed, only NF-kB1 and IL8 demonstrated a statistically
significant rise in the seroconverted group relative to the
group that did not seroconvert (Figure 2). A modest increase
(1.67-fold) was observed in CCL4 in the group positive for se-
roconversion, although this did not reach statistical signifi-
cance (P = .06). Other genes associated with the IFN response,
such as MX1, STAT1, and IRF7, did not seem to be affected.
These data confirm that subjects who seroconverted had a de-
tectable immune response to the vaccine in blood cells.
Nasal Antibody Responses and Nasal Cytokine Secretion
To evaluate the local response to virus replication, a nasal
wash specimen was collected from subjects 3 days after admin-
istration of the vaccine and was compared to a nasal wash
sample collected 30 days after vaccination. An ELISA was
performed to quantify the HA-specific IgA antibodies, using
the rHA from influenza A virus subtype H1N1 as an immu-
noadsorbent. In contrast to results obtained by HAI in serum,
26 subjects (33%) showed a significant, ≥2-fold increase in
IgA at day 30, which has been proposed by others to be a pos-
itive nasal antibody response [8] (Table 3). Moreover, the
magnitude of the HA-specific IgA antibody response between
the subjects showed large variation, from 2- to 22-fold
(Figure 3A).
The nasal wash samples were analyzed in a multiplex
ELISA assay to determine cytokine expression. IP-10 and
MCP-1 were detected in 100% and G-CSF in 84% of subjects
on day 3 after vaccination, while only 34% of the subjects had
detectable IFN-α2 on day 3 after vaccination. The cytokine
levels in the nasal wash samples on day 30 and the levels ob-
served 3 days after vaccination for all 79 subjects are displayed
as a heat map (Figure 3B). The cytokine levels on day 30 after
vaccination were considered to be baseline values because
nasal wash was not performed prior to vaccine, owing to
concern that this procedure might interfere with the adminis-
tration and absorption of the intranasal vaccination. Moreover,
nasal cytokine levels are reported to return to baseline levels
by day 9 after LAIV receipt [26] and by day 8 after experimen-
tal influenza virus infection [27].
The heat map shows an increase in IP-10 and G-CSF levels
after LAIV receipt in the majority of the patients. A total of 62
(78%), 42 (53%), 27 (34%), and 17 patients (21%) showed an
increase in IP-10, G-CSF, MCP-1, and IFN-α2 levels, respec-
tively, on day 3 after vaccination. Among those cytokines, we
observed a statistically significant increase in IP-10 (P < .0001)
and G-CSF (P = .0005) levels after LAIV administration. In
contrast, no statistically significant differences were observed
for MCP-1 and IFN-α2 levels (Figure 3C).
Table 3. Findings From Enzyme-Linked Immunosorbent Assay
(ELISA) to Determine the Hemagglutinin-Specific Immunoglobulin
A (IgA) Antibody Response to A/California/04/2009 (H1N1) Influen-



















3.18 ± 1.75 5.03 ± 2.52 26/26 (100) .0033
Data are mean ± SD, unless otherwise indicated.
a Defined as a ≥2-fold increase in titer between samples obtained on day 30
and day 3 after vaccination. Data are no. of seroconverted vaccine recipients/
total no. of vaccine recipients (%).
b Comparison of vaccine antibody levels 30 d and 3 d after vaccination,
calculated by a 2-tailed unpaired Student t test.
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Nasal Mucosa Gene Signature Profile After LAIV Receipt
Gene expression in nasal mucosa was measured to determine
whether an IFN signature existed in the mucosa of the IgA
converters. We analyzed different IFN-stimulated genes, in-
cluding MX1, STAT-1, IRF7, RIG1, and BST2. All IFN-stimu-
lated genes were statistically significantly upregulated on day 3
after vaccination (Figure 4). These results indicated that LAIV
induces a local inflammatory response that may influence
LAIV efficacy.
DISCUSSION
We performed a prospective cohort study to identify factors
associated with immunological responses to LAIV systemically
and in the local respiratory tract during the 2010–2011
influenza season in a generally healthy adult population. Two
major questions asked in this study were whether LAIV trig-
gers a systemic immune response, including production of
HA-specific antibodies, production of cytokines, and innate
cell activation, and whether similar changes occurring in the
upper respiratory cavity can be measured.
By use of HAI, we found that only 9% of subjects serocon-
verted, which is less than previously reported [3]. However, a
more sensitive method (IHC) revealed that 24% showed an
enhancement in serum antibody response. IHC is probably
more sensitive because it identifies antibodies binding to dif-
ferent antigens, including HA and NA epitopes present on the
cell surface. No changes in serum cytokine levels were found
on day 3 after vaccination either in the full group or in the
seroconverters only. However, monocytes collected from
Figure 3. Analysis of mucosal immunity induced by live attenuated influenza vaccine (LAIV) receipt. A, Nasal hemagglutinin-specific immunoglobulin
A (IgA) antibody to influenza A virus subtype H1N1 are shown as fold-changes on day 30 after LAIV vaccination relative to day 3. Continued line
represents the subjects with a ≥2-fold increase above the baseline value. Dashed line denotes a fold-change equal to 1 (ie, no change). B, Nasal
cytokine concentrations on day 3 and 30 after vaccination were analyzed by multiplex enzyme-linked immunosorbent assay and are represented as a
heat map. Each column represents 1 cytokine. The Basal column represents the concentration on day 30, and the Post column represents the concentra-
tion on day 3 after vaccination. C, Box plots of cytokine levels from nasal wash specimens on day 30 after vaccination (baseline) and day 3 after
vaccination. The top and bottom of each rectangle give the 75th and 25th percentiles, respectively, while the bold line in the middle of the rectangle
gives the 50th percentile. Outliers are indicated by open circles. *P < .0005, by the paired Wilcoxon test.
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subjects with seroconversion showed a mildly activated pheno-
type, as manifested by a rise in NF-kB and interleukin 8
mRNAs. These results are in agreement with the findings by
Nakaya et al [13], showing upregulation of different genes in
monocytes 7 days after vaccination. Our data suggest that
monitoring the status of blood monocytes might be an ex-
tremely sensitive assay for detecting systemic immune activa-
tion. Moreover, the demonstration that this vaccine is
protective reinforces the division between mucosal and sys-
temic immunity and mandates that measures of efficacy
should be chosen appropriately.
LAIV depends on some level of virus replication to generate
an adaptive immune response. Two immune elements that
might interfere with that are preformed neutralizing antibod-
ies and very efficient innate immune activation. Thus, we eval-
uated seroconversion with respect to these host factors. Our
data suggests that subjects lacking preformed antibody to the
virus were more likely to generate a systemic response to
LAIV. Of the 7 subjects who seroconverted by HAI, 6 had no
preformed antibodies.
Our studies in mouse models of virus infection emphasized
the systemic rise in levels of serum cytokines that function in
successful viral clearance [28]. In contrast to findings for mice,
we documented great variation in human serum cytokine pro-
files [16], and indeed, similar variation in cytokine levels was
observed in prevaccine serum from patients in this study.
Therefore, we asked whether cytokine profile variation might
influence vaccine efficacy. Type I IFN levels vary greatly, and
subjects who seroconverted had slightly lower levels of IFN-α2
at vaccination. Because of the low percentage of seroconvert-
ers, a statistically significant difference was not observed. In
contrast, the observation that subjects who seroconverted had
lower serum concentrations of G-CSF at vaccination was quite
striking.
As previously reported, LAIV receipt resulted in an increase
of IgA antibodies in nasal wash samples [5]. To further charac-
terize the response elicited by the vaccine, we also determined
the cytokine expression and gene profile in the nasal mucosa.
Nasal wash could not be administered prior to vaccination
because it is not part of standard clinical care and might influ-
ence the vaccine efficacy. Therefore, we used the nasal wash
sample obtained 30 days after vaccination as a baseline to
analyze the immediate (day 3) cytokine response to LAIV, and
we used the day 3 nasal wash specimen as baseline for the IgA
response on day 30. Although IFN was not detected in the
nasal washes, the rise in the IP-10 level in 78% of the patients,
as well as the induction of IFN-stimulated genes in mucosal
cells, likely resulted from release of IFN at a level below the
lower limit of detection. G-CSF expression was also increased
in the majority of patients. This IFN signature observed in the
nasal mucosa may be the most sensitive measure of successful
LAIV vaccination.
Figure 4. Nasal mucosal gene signature profiles after live attenuated influenza vaccine receipt. RNA amplification and quantitative reverse transcrip-
tion polymerase chain reaction of cell pellets of nasal wash specimens obtained on days 3 and 30 after vaccination were performed to analyze the
expression of the interferon-regulated genes MX1, STAT1, BST2, IRF7, and RIG1. Error bars represent the standard error of the mean. *P < .05.
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One reason this study was undertaken was to determine
whether the study of LAIV could provide information useful
for understanding influenza virus infection in humans. The
observation that subjects with lower levels of G-CSF were
more likely to seroconvert is novel and may have implications
for future studies of vaccination and infection. G-CSF is in-
volved in the generation and recruitment of neutrophils,
among other functions [29, 30]. It is possible that phagocytosis
is an important control mechanism in the upper respiratory
tract and that, if phagocytosis is reduced, more virus replica-
tion and possibly dissemination might occur, leading to sys-
temic responses. Examination of nasal wash specimens
revealed that the G-CSF level clearly rose in response to the
vaccine, suggesting that G-CSF has an important antiviral
function, which probably involves recruiting cells to and/or
activating cells in the nasal cavity. We speculate that these
cells may function during influenza virus infection to restrict
virus to the upper airway, preventing dissemination to the
lungs. Many of the less severe influenza infections are restrict-
ed to the upper airway. In response to LAIV, a lower G-CSF
level may indicate a weaker innate response, allowing sufficient
viral replication for an optimum adaptive response. Thus,
mucosal cytokines may serve as useful indicators of sensitivity
to more-severe infection.
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